• Scott S. ShortEmail author
  • Stephanie C. Papillon
  • Henri R. Ford
Reference work entry


Sepsis in children is a complex process that remains incompletely understood. Nevertheless, clarification in the diagnosis of sepsis and identification of host immunologic pathways as well as bacterial virulence factors have led to greatly improved understanding of the disease processes. Ultimately, this has resulted in improved management algorithms and improved outcomes with more than fivefold decrement in mortality over the last 50 years. This chapter will outline the current understanding of epidemiology, pathophysiology, management, and therapeutic strategies for pediatric sepsis.


Pediatric sepsis Septic shock Neonatal sepsis 


  1. Bojalil R, Mata-Gonzalez MT, Sanchez-Munoz F, Yee Y, Argueta I, Bolanos L, et al. Anti-tumor necrosis factor VNAR single domains reduce lethality and regulate underlying inflammatory response in a murine model of endotoxic shock. BMC Immunol. 2013;14:17. Epub 2013/04/04.PubMedPubMedCentralCrossRefGoogle Scholar
  2. Brierley J, Carcillo JA, Choong K, Cornell T, Decaen A, Deymann A, et al. Clinical practice parameters for hemodynamic support of pediatric and neonatal septic shock: 2007 update from the American College of Critical Care Medicine. Crit Care Med. 2009;37(2):666–88. Epub 2009/03/28.PubMedPubMedCentralCrossRefGoogle Scholar
  3. Brocklehurst P, Farrell B, King A, Juszczak E, Darlow B, Haque K, et al. Treatment of neonatal sepsis with intravenous immune globulin. N Engl J Med. 2011;365(13):1201–11. Epub 2011/10/04.PubMedCrossRefPubMedCentralGoogle Scholar
  4. Caresta E, Papoff P, Benedetti Valentini S, Mancuso M, Cicchetti R, Midulla F, et al. What’s new in the treatment of neonatal shock. J Matern Fetal Neonatal Med. 2011;24(Suppl 1):17–9. Epub 2011/09/08.PubMedCrossRefPubMedCentralGoogle Scholar
  5. Chan CM, Mitchell AL, Shorr AF. Etomidate is associated with mortality and adrenal insufficiency in sepsis: a meta-analysis*. Crit Care Med. 2012;40(11):2945–53. Epub 2012/09/14.PubMedCrossRefPubMedCentralGoogle Scholar
  6. Chaplin DD. Overview of the immune response. J Allergy Clin Immunol. 2010;125(2 Suppl 2):S3–23. Epub 2010/03/05.PubMedPubMedCentralCrossRefGoogle Scholar
  7. Coopersmith CM, Wunsch H, Fink MP, Linde-Zwirble WT, Olsen KM, Sommers MS, et al. A comparison of critical care research funding and the financial burden of critical illness in the United States. Crit Care Med. 2012;40(4):1072–9. Epub 2011/12/29.PubMedCrossRefPubMedCentralGoogle Scholar
  8. Cruz AT, Perry AM, Williams EA, Graf JM, Wuestner ER, Patel B. Implementation of goal-directed therapy for children with suspected sepsis in the emergency department. Pediatrics. 2011;127(3):e758–66. Epub 2011/02/23.PubMedCrossRefPubMedCentralGoogle Scholar
  9. Czaja AS, Zimmerman JJ, Nathens AB. Readmission and late mortality after pediatric severe sepsis. Pediatrics. 2009;123(3):849–57. Epub 2009/03/04.PubMedCrossRefPubMedCentralGoogle Scholar
  10. Dellinger RP, Levy MM, Rhodes A, Annane D, Gerlach H, Opal SM, et al. Surviving sepsis campaign: international guidelines for management of severe sepsis and septic shock, 2012. Intensive Care Med. 2013;39(2):165–228. Epub 2013/01/31.PubMedCrossRefGoogle Scholar
  11. Goldstein B, Giroir B, Randolph A. International pediatric sepsis consensus conference: definitions for sepsis and organ dysfunction in pediatrics. Pediatr Crit Care Med. 2005;6(1):2–8. Epub 2005/01/08.PubMedCrossRefGoogle Scholar
  12. Granja C, Povoa P, Lobo C, Teixeira-Pinto A, Carneiro A, Costa-Pereira A. The predisposition, infection, response and organ failure (Piro) sepsis classification system: results of hospital mortality using a novel concept and methodological approach. PLoS One. 2013;8(1):e53885. Epub 2013/01/26.PubMedPubMedCentralCrossRefGoogle Scholar
  13. Jekarl DW, Lee SY, Lee J, Park YJ, Kim Y, Park JH, et al. Procalcitonin as a diagnostic marker and IL-6 as a prognostic marker for sepsis. Diagn Microbiol Infect Dis. 2013;75(4):342–7. Epub 2013/02/09.PubMedCrossRefPubMedCentralGoogle Scholar
  14. Jiang LN, Yao YM, Sheng ZY. The role of regulatory T cells in the pathogenesis of sepsis and its clinical implication. J Interf Cytokine Res. 2012;32(8):341–9. Epub 2012/07/18.CrossRefGoogle Scholar
  15. Kissoon N, Orr RA, Carcillo JA. Updated American College of Critical Care Medicine – pediatric advanced life support guidelines for management of pediatric and neonatal septic shock: relevance to the emergency care clinician. Pediatr Emerg Care. 2010;26(11):867–9. Epub 2010/11/09.PubMedCrossRefPubMedCentralGoogle Scholar
  16. Klein Klouwenberg PM, Ong DS, Bonten MJ, Cremer OL. Classification of sepsis, severe sepsis and septic shock: the impact of minor variations in data capture and definition of SIRS criteria. Intensive Care Med. 2012;38(5):811–9. Epub 2012/04/06.PubMedCrossRefPubMedCentralGoogle Scholar
  17. Klos A, Tenner AJ, Johswich KO, Ager RR, Reis ES, Kohl J. The role of the anaphylatoxins in health and disease. Mol Immunol. 2009;46(14):2753–66. Epub 2009/05/30.PubMedPubMedCentralCrossRefGoogle Scholar
  18. Kreymann KG, de Heer G, Nierhaus A, Kluge S. Use of polyclonal immunoglobulins as adjunctive therapy for sepsis or septic shock. Crit Care Med. 2007;35(12):2677–85. Epub 2007/12/13.PubMedPubMedCentralGoogle Scholar
  19. Lacroix J, Demaret P, Tucci M. Red blood cell transfusion: decision making in pediatric intensive care units. Semin Perinatol. 2012;36(4):225–31. Epub 2012/07/24.PubMedCrossRefPubMedCentralGoogle Scholar
  20. Laskin DL, Sunil VR, Gardner CR, Laskin JD. Macrophages and tissue injury: agents of defense or destruction? Annu Rev Pharmacol Toxicol. 2011;51:267–88. Epub 2010/10/05.PubMedPubMedCentralCrossRefGoogle Scholar
  21. Lawn JE, Cousens S, Zupan J. 4 million neonatal deaths: when? Where? Why? Lancet. 2005;365(9462):891–900. Epub 2005/03/09.PubMedCrossRefGoogle Scholar
  22. Lewis AL, Lewis WG. Host sialoglycans and bacterial sialidases: a mucosal perspective. Cell Microbiol. 2012;14(8):1174–82. Epub 2012/04/24.PubMedCrossRefGoogle Scholar
  23. Liu G, Place AT, Chen Z, Brovkovych VM, Vogel SM, Muller WA, et al. ICAM-1-activated Src and eNOS signaling increase endothelial cell surface PECAM-1 adhesivity and neutrophil transmigration. Blood. 2012;120(9):1942–52. Epub 2012/07/19.PubMedPubMedCentralCrossRefGoogle Scholar
  24. Lopez-Alarcon M, Bernabe-Garcia M, del Valle O, Gonzalez-Moreno G, Martinez-Basilea A, Villegas R. Oral administration of docosahexaenoic acid attenuates interleukin-1beta response and clinical course of septic neonates. Nutrition. 2012;28(4):384–90. Epub 2011/11/15.PubMedCrossRefGoogle Scholar
  25. Lutz HU. How immune complexes from certain IgG NAbs and any F(ab’)(2) can mediate excessive complement activation. Adv Exp Med Biol. 2012;750:186–96. Epub 2012/08/21.PubMedCrossRefGoogle Scholar
  26. MacLaren G, Butt W, Best D, Donath S. Central extracorporeal membrane oxygenation for refractory pediatric septic shock. Pediatr Crit Care Med. 2011;12(2):133–6. Epub 2010/05/11.PubMedCrossRefGoogle Scholar
  27. Nurieva RI, Liu X, Dong C. Yin-Yang of costimulation: crucial controls of immune tolerance and function. Immunol Rev. 2009;229(1):88–100. Epub 2009/05/12.PubMedPubMedCentralCrossRefGoogle Scholar
  28. Ogawa J, Sasahara A, Yoshida T, Sira MM, Futatani T, Kanegane H, et al. Role of transforming growth factor-beta in breast milk for initiation of IgA production in newborn infants. Early Hum Dev. 2004;77(1–2):67–75. Epub 2004/04/29.PubMedCrossRefGoogle Scholar
  29. Ohlsson A, Lacy J. Intravenous immunoglobulin for suspected or subsequently proven infection in neonates. Cochrane Database Syst Rev. 2010;3(3):CD001239. Epub 2010/03/20.Google Scholar
  30. Ohlsson A, Lacy JB. Intravenous immunoglobulin for suspected or proven infection in neonates. Cochrane Database Syst Rev. 2015;3(3):CD001239.Google Scholar
  31. de Oliveira CF, de Oliveira DS, Gottschald AF, Moura JD, Costa GA, Ventura AC, et al. ACCM/PALS haemodynamic support guidelines for paediatric septic shock: an outcomes comparison with and without monitoring central venous oxygen saturation. Intensive Care Med. 2008;34(6):1065–75. Epub 2008/03/29.PubMedCrossRefPubMedCentralGoogle Scholar
  32. Opal SM. Concept of PIRO as a new conceptual framework to understand sepsis. Pediatr Crit Care Med. 2005;6(Suppl 3):S55–60. Epub 2005/04/29.PubMedCrossRefPubMedCentralGoogle Scholar
  33. Pabst O. New concepts in the generation and functions of IgA. Nat Rev Immunol. 2012;12(12):821–32. Epub 2012/10/30.PubMedCrossRefPubMedCentralGoogle Scholar
  34. Payen JF, Dupuis C, Trouve-Buisson T, Vinclair M, Broux C, Bouzat P, et al. Corticosteroid after etomidate in critically ill patients: a randomized controlled trial. Crit Care Med. 2012;40(1):29–35. Epub 2011/09/20.PubMedCrossRefPubMedCentralGoogle Scholar
  35. Qiu P, Cui X, Barochia A, Li Y, Natanson C, Eichacker PQ. The evolving experience with therapeutic TNF inhibition in sepsis: considering the potential influence of risk of death. Expert Opin Investig Drugs. 2011;20(11):1555–64. Epub 2011/10/04.PubMedPubMedCentralCrossRefGoogle Scholar
  36. Ranieri VM, Thompson BT, Barie PS, Dhainaut JF, Douglas IS, Finfer S, et al. Drotrecogin alfa (activated) in adults with septic shock. N Engl J Med. 2012;366(22):2055–64. Epub 2012/05/24.PubMedCrossRefPubMedCentralGoogle Scholar
  37. Rice TW, Wheeler AP, Morris PE, Paz HL, Russell JA, Edens TR, et al. Safety and efficacy of affinity-purified, anti-tumor necrosis factor-alpha, ovine fab for injection (CytoFab) in severe sepsis. Crit Care Med. 2006;34(9):2271–81. Epub 2006/07/01.PubMedCrossRefPubMedCentralGoogle Scholar
  38. Rogosch T, Kerzel S, Hoss K, Hoersch G, Zemlin C, Heckmann M, et al. IgA response in preterm neonates shows little evidence of antigen-driven selection. J Immunol. 2012;189(11):5449–56. Epub 2012/10/30.PubMedPubMedCentralCrossRefGoogle Scholar
  39. Sarantis H, Grinstein S. Subversion of phagocytosis for pathogen survival. Cell Host Microbe. 2012;12(4):419–31. Epub 2012/10/23.PubMedCrossRefPubMedCentralGoogle Scholar
  40. Shime N, Kawasaki T, Saito O, Akamine Y, Toda Y, Takeuchi M, et al. Incidence and risk factors for mortality in paediatric severe sepsis: results from the national paediatric intensive care registry in Japan. Intensive Care Med. 2012;38(7):1191–7. Epub 2012/04/25.PubMedCrossRefPubMedCentralGoogle Scholar
  41. Smith RP, Baltch AL, Ritz WJ, Michelsen PB, Bopp LH. IFN-gamma enhances killing of methicillin-resistant Staphylococcus aureus by human monocytes more effectively than GM-CSF in the presence of daptomycin and other antibiotics. Cytokine. 2010;51(3):274–7. Epub 2010/06/29.PubMedCrossRefPubMedCentralGoogle Scholar
  42. Standage SW, Wong HR. Biomarkers for pediatric sepsis and septic shock. Expert Rev Anti-Infect Ther. 2011;9(1):71–9. Epub 2010/12/22.PubMedPubMedCentralCrossRefGoogle Scholar
  43. Todd SR, Sim V, Moore LJ, Turner KL, Sucher JF, Moore FA. The identification of thyroid dysfunction in surgical sepsis. J Trauma Acute Care Surg. 2012;73(6):1457–60. Epub 2012/11/29.PubMedCrossRefPubMedCentralGoogle Scholar
  44. Wang HE, Shapiro NI, Griffin R, Safford MM, Judd S, Howard G. Inflammatory and endothelial activation biomarkers and risk of sepsis: a nested case-control study. J Crit Care. 2013;28(5):549–55. Epub 2013/02/19.PubMedCrossRefPubMedCentralGoogle Scholar
  45. Watson RS, Carcillo JA, Linde-Zwirble WT, Clermont G, Lidicker J, Angus DC. The epidemiology of severe sepsis in children in the United States. Am J Respir Crit Care Med. 2003;167(5):695–701. Epub 2002/11/16.PubMedCrossRefPubMedCentralGoogle Scholar
  46. Webb SA, Kahler CM. Bench-to-bedside review: bacterial virulence and subversion of host defences. Crit Care. 2008;12(6):234. Epub 2008/11/19.PubMedPubMedCentralCrossRefGoogle Scholar
  47. Wolfler A, Silvani P, Musicco M, Antonelli M, Salvo I. Incidence of and mortality due to sepsis, severe sepsis and septic shock in Italian pediatric intensive care units: a prospective national survey. Intensive Care Med. 2008;34(9):1690–7. Epub 2008/05/27.PubMedCrossRefPubMedCentralGoogle Scholar
  48. Wong HR, Cvijanovich N, Wheeler DS, Bigham MT, Monaco M, Odoms K, et al. Interleukin-8 as a stratification tool for interventional trials involving pediatric septic shock. Am J Respir Crit Care Med. 2008;178(3):276–82. Epub 2008/05/31.PubMedPubMedCentralCrossRefGoogle Scholar
  49. Wong HR, Salisbury S, Xiao Q, Cvijanovich NZ, Hall M, Allen GL, et al. The pediatric sepsis biomarker risk model. Crit Care. 2012;16(5):R174. Epub 2012/10/03.PubMedPubMedCentralCrossRefGoogle Scholar
  50. Workman JK, Ames SG, Reeder RW, et al. Treatment of pediatric septic shock with the surviving sepsis campaign guidelines and PICU patient outcomes. Pediatr Crit Care Med. 2016;17(10):e451–8.PubMedCrossRefGoogle Scholar
  51. Wynn JL, Levy O. Role of innate host defenses in susceptibility to early-onset neonatal sepsis. Clin Perinatol. 2010;37(2):307–37. Epub 2010/06/24.PubMedPubMedCentralCrossRefGoogle Scholar
  52. Wynn JL, Wong HR. Pathophysiology and treatment of septic shock in neonates. Clin Perinatol. 2010;37(2):439–79. Epub 2010/06/24.PubMedPubMedCentralCrossRefGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2020

Authors and Affiliations

  • Scott S. Short
    • 1
    Email author
  • Stephanie C. Papillon
    • 1
  • Henri R. Ford
    • 1
  1. 1.Division of Pediatric SurgeryChildren’s Hospital Los AngelesLos AngelesUSA

Personalised recommendations